

Medical Policy Manual **Approved Rev: Do Not Implement until 9/30/26**

Beremagene Geperpavec-svdt (Vyjuvek™)

IMPORTANT REMINDER

We develop Medical Policies to provide guidance to Members and Providers. This Medical Policy relates only to the services or supplies described in it. The existence of a Medical Policy is not an authorization, certification, explanation of benefits or a contract for the service (or supply) that is referenced in the Medical Policy. For a determination of the benefits that a Member is entitled to receive under his or her health plan, the Member's health plan must be reviewed. If there is a conflict between the medical policy and a health plan or government program (e.g., TennCare), the express terms of the health plan or government program will govern.

POLICY

INDICATIONS

The indications below including FDA-approved indications and compendial uses are considered a covered benefit provided that all the approval criteria are met and the member has no exclusions to the prescribed therapy.

FDA-Approved Indications

Vyjuvek is indicated for the treatment of wounds in adult and pediatric patients with dystrophic epidermolysis bullosa with mutation(s) in the collagen type VII alpha 1 chain (COL7A1) gene.

All other indications are considered experimental/investigational and not medically necessary.

DOCUMENTATION

Submission of the following information is necessary to initiate the prior authorization review:

- Medical records documenting clinical manifestations of disease.
- Genetic test results confirming a **pathogenic or likely pathogenic variant** in the COL7A1 gene.

PRESCRIBER SPECIALTIES

This medication must be prescribed by or in consultation with a dermatologist or wound care specialist.

COVERAGE CRITERIA

Dystrophic Epidermolysis Bullosa (DEB)

Authorization of 12 months may be granted for treatment of wounds in members with dystrophic epidermolysis bullosa (DEB) when all of the following criteria are met:

- Member has clinical manifestations of disease (e.g., extensive skin blistering, skin erosions, scarring).
- Member has genetic test results confirming a **pathogenic or likely pathogenic variant** in the COL7A1 gene.
- Member has one or more open wounds that will be treated (i.e., target wounds).
- Target wound(s) meet all of the following:
 - Wound is clear in appearance and does not appear to be infected
 - Wound has adequate granulation tissue and vascularization
 - Member does not have a history of squamous cell carcinoma in the affected wound(s) that will receive treatment.
- **Member has not received a skin graft in the past three months.**

Medical Policy Manual **Approved Rev: Do Not Implement until 9/30/26**

- Member will not receive Zevaskyn (prademagene zamikeracel) or use Filsuvez (birch triterpenes) on wounds that have previously been treated with Vyjuvek.
- The requested medication will be administered once weekly to the affected wound(s) by a healthcare professional, patient, or caregiver either at a healthcare professional setting (e.g., clinic) or a home setting.
- The requested medication will not be administered to wound(s) that are currently healed.

APPLICABLE TENNESSEE STATE MANDATE REQUIREMENTS

BlueCross BlueShield of Tennessee's Medical Policy complies with Tennessee Code Annotated Section 56-7-2352 regarding coverage of off-label indications of Food and Drug Administration (FDA) approved drugs when the off-label use is recognized in one of the statutorily recognized standard reference compendia or in the published peer-reviewed medical literature.

ADDITIONAL INFORMATION

For appropriate chemotherapy regimens, dosage information, contraindications, precautions, warnings, and monitoring information, please refer to one of the standard reference compendia (e.g., the NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®) published by the National Comprehensive Cancer Network®, Drugdex Evaluations of Micromedex Solutions at Truven Health, or The American Hospital Formulary Service Drug Information).

REFERENCES

1. Vyjuvek [package insert]. Pittsburgh, PA: Krystal Biotech, Inc.; September 2025.
2. Guide SV, Gonzalez ME, Bağcı IS, et al. Trial of Beremagene Geperpavec (B-VEC) for Dystrophic Epidermolysis Bullosa. N Engl J Med. 2022;387(24):2211-2219.

EFFECTIVE DATE

9/30/2026

ID_CHS_2026